Moxa quality and curative effect evaluation model based on terahertz technology
Through terahertz spectroscopy detection and medical index analysis of rat moxa treatment, an evaluation model of moxa quality and efficacy was established, which solved the problem of poor evaluation of moxa quality and efficacy in the existing technology, and achieved rapid and lossless Detection and evaluation significantly improve the stability of treatment effects and detection efficiency.
Patent Information
- Application Number
- CN202410898580.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-26
AI Technical Summary
The lack of effective methods in the prior art to quickly and non-destructively evaluate the quality and efficacy of moxa velvet, which leads to unstable therapeutic effects. Especially in moxa velvet treatment, the production ratio and storage years of moxa velvet affect the content of drug ingredients and the treatment. Effect.
Using a spectral detection method based on terahertz technology, the terahertz full-band absorption spectral signal of moxa velvet made in different proportions is established, and the medical index data of rat moxa velvet is established to evaluate the quality and efficacy of moxa velvet. , including the use of FTIR spectrometer to detect the absorption spectrum of moxa velvet samples, stratified analysis of medical indicators in rats, and construction of PLS prediction models to determine the impact of drug components.
It realizes rapid and safe detection of the impact of the differences in drug composition of moxa wool in actual treatment, combines the research on the quality of moxa wool and the comprehensive evaluation of clinical efficacy, saves sample costs, improves detection efficiency, and can significantly display different proportions of moxa Differences in therapeutic effects.
Smart Images

Figure CN119028532A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of far-infrared spectroscopy in the terahertz band, and in particular to an evaluation model for the quality and efficacy of moxa based on terahertz technology. Background Art
[0002] Mugwort is a perennial herb belonging to the genus Artemisia of the Asteraceae family. It mainly contains volatile oils, flavonoids, terpenes and other ingredients, and has multiple pharmacological effects such as antibacterial, hemostatic, analgesic, anti-inflammatory and antioxidant. Mugwort is a soft and fine cotton-like substance obtained by repeatedly drying, pounding and crushing wormwood, and sieving out impurities and dust. This processing process helps to increase the content of effective drug ingredients per unit volume, making it easier to play a role in treatments such as moxibustion, especially in inflammatory pain. Pharmacological studies have shown that the drug ingredients with higher content in moxa include pinolein in moxa volatile oil and flavonoid compounds in non-volatile components. However, since moxa is affected by factors such as production ratio, processing method and storage period, the content of effective drug ingredients also changes, resulting in unstable or even reduced therapeutic effects.
[0003] Terahertz waves are between microwaves and infrared waves in the electromagnetic spectrum, and have the characteristics of both microwaves and infrared waves. They usually refer to electromagnetic waves with a frequency range of 0.1-10THz, corresponding to a wavelength range of 30μm-3mm. They can penetrate and interact with many commonly used materials. They are non-ionizing radiation, and their low photon energy usually does not destroy the sample tissue structure. Its advantages mainly include: 1) Penetration characteristics, terahertz waves can penetrate many non-conductive materials to detect the internal structure of the sample; 2) Transient characteristics, terahertz waves can detect rapid dynamic changes between molecules; 3) Coherence characteristics, terahertz waves provide high-resolution and high-sensitivity measurement capabilities, which can be used to accurately measure subtle changes in molecular structure and interaction forces; 4) Safety characteristics, terahertz waves can achieve non-destructive testing of biological tissues. In addition, in terahertz spectroscopy, even very small changes in molecular configuration will have significant spectral differences, so terahertz can be used to identify isomers. Pineneol is an isomer of monoterpene alcohol, and flavonoids are a key class of polyphenolic secondary metabolites, including isomers of flavonoids and their hydrogenated reduction products. Therefore, the use of terahertz spectroscopy to detect pineneol and flavonoids in moxa has obvious advantages.
[0004] At present, the research on the quality of moxa is still limited to theoretical quality testing, lacking a comprehensive evaluation combined with actual clinical efficacy. The production ratio of moxa will directly affect the content of pinolene and flavonoid compounds, which will in turn show differences in the effect of moxibustion treatment. Therefore, it is very meaningful to provide an effective and rapid method to expand the quality evaluation of moxa from the detection of a single drug component to the field of actual therapeutic effects. Summary of the invention
[0005] In view of the shortcomings of the prior art, the purpose of the present invention is to provide an evaluation model for the quality and efficacy of moxa based on terahertz technology, which saves sample costs, improves detection efficiency, and achieves a better combination with the actual clinical efficacy. In order to achieve the above-mentioned purpose and other advantages according to the present invention, an evaluation model for the quality and efficacy of moxa based on terahertz technology is provided, comprising the following steps:
[0006] S1. Detect the terahertz full-band absorption spectrum signals of moxa made with different proportions by terahertz spectroscopy technology;
[0007] S2. Rats were divided into three moxibustion groups and a model group according to the principle of stratification by weight;
[0008] S3. Rats in the moxibustion group were treated with moxibustion using high-quality moxa wool. Six medical indicators were recorded to evaluate the treatment effect. The three values of behavioral assessment were compared between groups. The variability between the observed values was compared to determine whether the effect on the outcome variable was significant. At this time, the six medical indicator information was recorded before the intervention and after the 2nd, 4th, and 7th intervention (3rd, 5th, 9th, and 15th days), and the indicator information was analyzed using IBM SPSS Statistics 26.0. The indicator information was analyzed using IBM SPSS Statistics 26.0, and the results were presented in the form of mean ± standard error. When p < 0.05, the difference was considered statistically significant.
[0009] S4. One-way ANOVA was used to determine whether there were significant differences in the values of TNF-α, IL-1β, and IL-6 measured on the 3rd, 5th, 9th, and 15th days among the four groups of rats. IBM SPSS Statistics 26.0 was used to analyze the index information and the results were presented in the form of mean ± standard error. When p < 0.05, the difference was considered statistically significant.
[0010] S5. The full-band terahertz spectra of moxa at 10:1, 20:1 and 30:1 were selected to establish a PLS prediction model with six groups of medical indicators of rats after moxibustion treatment. The PLS model matrix was constructed according to the ratio of 2:1 between the modeling set and the prediction set. The R 2 And RMSE can determine the accuracy of the prediction model.
[0011] Preferably, the preparation of moxa in different proportions in step S1 comprises the following steps:
[0012] For moxa samples, they need to be ground into powder first; take out the moxa samples with tweezers, grind them preliminarily with agate utensils and put them into test tubes. To ensure sufficient grinding, the sample in the test tube is less than 1 / 3 of the volume; put a zirconia ball with a diameter of 2 mm into the test tube, and set the grinder to grind at a frequency of 70 Hz for 180 seconds; mix 5 mg of moxa and 40 mg of COC evenly, put them into a mold, and squeeze them with 5t pressure for 2 minutes to form a 1 mm thin sheet. The experimental mass loss is controlled within 1%.
[0013] Preferably, in step S1, FTIR is used as the terahertz spectrum detection equipment to measure the absorption spectrum of the moxa sample at room temperature of 22°C; specifically, a water-cooled mercury lamp is used as the light source, the signal-to-noise ratio of FTIR exceeds 10000:1, and the resolution is 4cm -1 128 scans were performed at a scanning speed of 5kHz to collect spectral data in the band of 0.9-20THz; FTIR has good scanning accuracy, and the jitter rate during the measurement process is less than 3%; before spectrum measurement, the spectrum software OPUS is used to scan the suppressed COC background, eliminate the background and record the scanning results; during the spectrum acquisition process, 30 spectra are collected for each sample.
[0014] Preferably, the spectral data obtained also includes using 10.1 and Origin 2018 were used to perform baseline correction, smoothing, and normalization of the spectra, and modeling analysis was performed; Gaussian-09 was used to calculate molecular vibrations; and IBM SPSS Statistics 26.0 was used for medical indicator data analysis.
[0015] Preferably, in step S2, a complete Freund's adjuvant injection method is used to establish a rat model of rheumatoid arthritis, so that the left hind paw of the rat develops varying degrees of redness, nodules and limited movement.
[0016] Preferably, step S3 specifically measures the surface temperature of the acupoints with a high-precision thermal imager to maintain it between 40°C and 45°C to reduce the result differences caused by temperature variables and prevent local excessive temperatures from causing burns to rats; the model group and the moxibustion group undergo the same grasping and fixation treatments, but no moxibustion treatment is performed.
[0017] Preferably, in step S3, before the intervention and after the 2nd, 4th and 7th interventions, i.e., on the 3rd, 5th, 9th and 15th days, the joint swelling degree (JSD), mechanical pain threshold (Paw Withdrawal Threshold, PWT) and paw withdrawal latency (PWL) are recorded in sequence; after the treatment, the concentrations of interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin 6 (IL-6) in the synovial tissue of the left hind paw joint of each group of rats are detected; the detection process is repeated three times and the average value is taken.
[0018] Preferably, step S5 specifically includes the following steps:
[0019] S51. Since the range of RMSE values has no upper and lower limits and is related to the actual data units, it is necessary to standardize the units when comparing different data sets and determine its reasonable range of values based on specific applications.
[0020] S52. Among the three PLS models for behavioral assessment, the modeling set R for JSD 2 The RMSE of the modeling set is 0.929, the RMSE of the prediction set is 0.169, and the R 2 is 0.907, the prediction set RMSE is 0.139, and the RPD is 3.279; for the PWT modeling set R 2 is 0.904, the RMSE of the modeling set is 0.0000578, and the R 2 is 0.933, the prediction set RMSE is 0.0000535, and the RPD is 3.863; for the modeling set R 2 is 0.957, the RMSE of the modeling set is 1.168, and the R 2 The predicted value is 0.932, the RMSE of the prediction set is 1.438, and the RPD is 3.835.
[0021] Compared with the prior art, the present invention has the following beneficial effects: the method of the present invention can quickly, non-destructively and safely detect samples made with different proportions, and more intuitively see the impact of the differences in the theoretical medicinal ingredients of moxa in actual treatment, and realize a comprehensive evaluation of the research on the quality of moxa and the actual clinical efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 Making terahertz spectra of moxa for different proportions of the moxa quality and efficacy evaluation model based on terahertz technology according to the present invention;
[0023] Figure 2A curve diagram showing changes in the JSD index during moxibustion treatment according to the moxa quality and efficacy evaluation model based on terahertz technology of the present invention;
[0024] Figure 3 It is a curve diagram of the change of PWT index in moxibustion treatment according to the evaluation model of moxa quality and efficacy based on terahertz technology of the present invention;
[0025] Figure 4 It is a curve diagram of the change of the PWL index in moxibustion treatment according to the moxa quality and efficacy evaluation model based on terahertz technology of the present invention;
[0026] Figure 5 The change of IL-1β index during moxibustion treatment according to the moxa quality and efficacy evaluation model based on terahertz technology of the present invention (p<0.05, 30:1 in the moxibustion group compared with other groups);
[0027] Figure 6 The change of TNF-α index during moxibustion treatment according to the moxa quality and efficacy evaluation model based on terahertz technology of the present invention (p<0.05, comparison between moxibustion group and model group);
[0028] Figure 7 This is the change of IL-6 index during moxibustion treatment according to the moxa quality and efficacy evaluation model based on terahertz technology of the present invention (p<0.05, comparison between different moxibustion groups). DETAILED DESCRIPTION
[0029] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] A Fourier transform-infrared spectrometer (FTIR Spectrometer) of the Bruker IFS66v / s model belonging to the VERTEX 80v series developed by the German BRUKER company was used. The experiment of the present invention was mainly carried out at a temperature of 22° C., and the number of spectral scans was 512 times.
[0031] The grinder used in the experiment is the MM400 model produced by Zeiss of Germany, which is mainly used for grinding and crushing samples to ensure uniform distribution of samples during subsequent sample preparation and testing.
[0032] The electronic balance used in the experiment is the MS105DU / A model produced by the Swiss company MettlerToledo, with an accuracy of 0.01 mg. It is mainly used for weighing samples to ensure that the error in the sample preparation process is within 5%.
[0033] The tablet press used in the experiment is the HY-24 model produced by Tianjin Tianguang Optical Instrument Co., Ltd., which is mainly used to prepare tablet samples for FTIR to ensure that the samples are pressed into 1 mm thin slices.
[0034] The high-precision thermal imager used in the experiment is the TP21B model produced by Hangzhou Hikvision Micro-Image Sensing Technology Co., Ltd. It is used for real-time detection of acupoint surface temperature during moxibustion treatment of rats to reduce unnecessary result differences caused by temperature variables and prevent burns to rats caused by excessive local temperature.
[0035] Embodiments of the present invention use 10.1 and Origin 2018 were used to perform baseline correction, smoothing, and normalization of the spectra, and modeling analysis was performed. Gaussian-09 was used to calculate molecular vibrations. IBM SPSS Statistics26.0 was used for medical indicator data analysis.
[0036] The moxa used in the embodiments of the present invention was purchased from Shanghai TCM University Shangxin Medical Technology Co., Ltd., and the production ratios were 3: 1, 5: 1, 8: 1, 10: 1, 20: 1 and 30: 1, respectively. 24 male Sprague-Dawley (SD) rats, weighing 180-240 g, were purchased from Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd. (Qualification Certificate: SCXK (Zhejiang) 2019-0001) and placed in the Animal Experiment Center of Shanghai University of Traditional Chinese Medicine for breeding.
[0037] Figure 1-7 , an evaluation model for the quality and efficacy of moxa based on terahertz technology, including the following steps:
[0038] The moxa sample needs to be ground into powder first. Take out the moxa samples made in different proportions with tweezers, grind them with agate utensils and put them into test tubes. To ensure sufficient grinding, the sample in the test tube is less than 1 / 3 of the volume. Put a zirconia ball with a diameter of 2mm into the test tube, and set the grinder to grind at a frequency of 70Hz for 180 seconds. Then mix 5mg of moxa and 40mg of COC evenly into the mold, squeeze it with 5t pressure for 2 minutes to form a 1mm thin sheet, and control the experimental mass loss within 1% to prepare samples for detecting the terahertz absorption spectrum signal of moxa.
[0039] FTIR was used as the terahertz spectrum detection equipment to measure the absorption spectrum of moxa samples at room temperature of 22°C. A water-cooled mercury lamp was used as the light source. The signal-to-noise ratio of FTIR exceeded 10000:1 and the resolution was 4cm -1 128 scans were performed at a scanning speed of 5kHz to collect spectral data in the band of 0.9-20THz. FTIR has good scanning accuracy, and the jitter rate during the measurement process is less than 3%. Before spectrum measurement, the spectrum software OPUS was used to scan the suppressed COC background, eliminate the background and record the scanning results. During the spectrum acquisition process, 30 spectra were collected for each sample, and the spectra were uniformly smoothed to reduce the impact of noise, delete the baseline, correct the baseline fluctuation, and improve the signal-to-noise ratio.
[0040] Rats were divided into four groups according to the principle of body weight stratification, namely three moxibustion groups and a model group, with 6 rats in each group. The rat model of rheumatoid arthritis was induced by complete Freund's adjuvant injection, which caused different degrees of redness, nodules and limited movement on the left hind paw of the rats. Moxibustion was performed on the "Zusanli" acupoint of the corresponding moxibustion group rats. In order to verify that the difference in efficacy was mainly due to the difference in the content of drug components in moxa of different qualities, the surface temperature of the acupoints was measured with a high-precision thermal imager to maintain it between 40℃ and 45℃ to reduce the difference in results caused by temperature variables and prevent local excessive temperature from causing burns to rats. The model group and the moxibustion group underwent the same grasping and fixation treatments, but no moxibustion treatment was performed.
[0041] Six medical index information was recorded before intervention and after the 2nd, 4th, and 7th intervention (3rd, 5th, 9th, and 15th days), and the index information was analyzed using IBM SPSS Statistics 26.0, the steps of which included:
[0042] Repeated measures ANOVA was used to compare the JSD, PWT and PWL values measured on the 3rd, 5th, 9th and 15th days of the four groups of rats. The variability between the observed values was compared to determine whether the effect on the outcome variable was significant. One-way ANOVA was used to determine whether there were significant differences in the TNF-α, IL-1β and IL-6 values measured on the 3rd, 5th, 9th and 15th days of the four groups of rats. Among them:
[0043] like Figure 2 As shown in the figure, for JSD, the 30:1 moxibustion group had statistically significant differences on the 5th day (p<0.05). On the 5th day, the 30:1 moxibustion group was 7.64±0.14mm; the 20:1 moxibustion group was 7.98±0.11mm; the 10:1 moxibustion group was 8.09±0.09mm; and the model group was 8.14±0.07mm, p<0.05. Figure 3As shown in the figure, for PWT, the 30:1 moxibustion group had statistically significant differences on the 5th, 9th and 15th days (p<0.05). On the 15th day, the 30:1 moxibustion group was 0.00519±0.00019g; the 20:1 moxibustion group was 0.00509±0.00023g; the 10:1 moxibustion group was 0.00498±0.00081g; and the model group was 0.00490±0.00016g, p<0.05. Figure 4 As shown, for PWL, there were statistical differences among the three moxibustion groups and the model group (p<0.05), the 30:1 moxibustion group was 27.33±0.57s; the 20:1 moxibustion group was 20.22±0.52s; the 10:1 moxibustion group was 14.35±0.48s; and the model group was 11.47±0.31s, p<0.05.
[0044] After the moxibustion treatment, the level of IL-1β in the ankle joint tissue of the rats in the moxibustion group was significantly lower than that in the model group, and there were significant statistical differences among the four groups (p<0.05). Figure 5 As shown in the figure, the 30:1 moxibustion group was 54.69±3.47ng / g; the 20:1 moxibustion group was 123.33±15.23ng / g; the 10:1 moxibustion group was 235.14±15.68ng / g; and the model group was 310.34±20.68ng / g, p<0.05. For TNF-, the TNF-α levels in the ankle joint tissues of the three moxibustion groups were significantly lower than those in the model group (p<0.05), but there was no significant difference between the different moxibustion groups. Figure 6 As shown in the figure, the 30:1 moxibustion group was 26.67±11.55ng / g; the 20:1 moxibustion group was 29.46±13.29ng / g; the 10:1 moxibustion group was 35.03±8.17ng / g; and the model group was 61.29±16.92ng / g, p<0.05. For IL-6, the IL-6 level of the moxibustion group after moxibustion treatment was lower than that of the model group, but there was no statistically significant difference among the four groups. Figure 3 As shown, the 30:1 moxibustion group was 129.63±49.99ng / g; the 20:1 moxibustion group was 148.25±52.75ng / g; the 10:1 moxibustion group was 142.92±35.11ng / g; and the model group was 263.05±102.87ng / g, p<0.05.
[0045] The R of JSD, PWT and PWL prediction models 2 The R values of the IL-1β prediction model were all greater than 0.90, and the RPD values were all greater than 3.2. 2 Greater than 0.94, RPD greater than 4.1.
[0046] The full-band terahertz spectra of moxa at 10:1, 20:1 and 30:1 were selected to establish a PLS prediction model with six groups of medical indicators of rats after moxibustion treatment. The PLS model matrix was constructed according to the ratio of modeling set to prediction set of 2:1. The R 2 The accuracy of the prediction model can be determined by PLS model and RMSE. The PLS model and prediction results are shown in Table 1:
[0047] Table 1. Moxibustion efficacy prediction model based on PLS
[0048]
[0049] The number of devices and processing scales described here are used to simplify the description of the present invention, and the application, modification and variation of the present invention will be obvious to those skilled in the art.
[0050] Although the embodiments of the present invention have been disclosed as above, they are not limited to the applications listed in the specification and implementation modes. They can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily implemented. Therefore, without departing from the general concept defined by the claims and the scope of equivalents, the present invention is not limited to the specific details and the illustrations shown and described herein.
Claims
1. An evaluation model for the quality and efficacy of moxa based on terahertz technology, characterized in that: The following steps are involved: S1. Detect the terahertz full-band absorption spectrum signals of moxa made with different proportions by terahertz spectroscopy technology; S2. Rats were divided into three moxibustion groups and a model group according to the principle of stratification by weight; S3. The rats in the moxibustion group were treated with moxibustion using high-quality moxa wool. Six medical indicators were recorded to evaluate the treatment effect. The three values of behavioral evaluation were compared between groups. The variability between the observed values was compared to determine whether the effect on the outcome variable was significant. S4. One-way ANOVA was used to determine whether there were significant differences in the values of TNF-α, IL-1β, and IL-6 measured on the 3rd, 5th, 9th, and 15th days among the four groups of rats; S5. The full-band terahertz spectra of moxa at 10:1, 20:1 and 30:1 were selected to establish a PLS prediction model with six groups of medical indicators of rats after moxibustion treatment. The PLS model matrix was constructed according to the ratio of 2:1 between the modeling set and the prediction set. The R 2 And RMSE can determine the accuracy of the prediction model.
2. The evaluation model of moxa quality and efficacy based on terahertz technology as claimed in claim 1, characterized in that: The preparation of moxa floss in different proportions in step S1 comprises the following steps: For moxa samples, they need to be ground into powder first; take out the moxa samples with tweezers, grind them preliminarily with agate utensils and put them into test tubes. To ensure sufficient grinding, the sample in the test tube is less than 1 / 3 of the volume; put a zirconia ball with a diameter of 2 mm into the test tube, and set the grinder to grind at a frequency of 70 Hz for 180 seconds; mix 5 mg of moxa and 40 mg of COC evenly, put them into a mold, and squeeze them with 5t pressure for 2 minutes to form a 1 mm thin sheet. The experimental mass loss is controlled within 1%.
3. The evaluation model of moxa quality and efficacy based on terahertz technology as claimed in claim 2, characterized in that: In step S1, FTIR is used as a terahertz spectrum detection device to measure the absorption spectrum of the moxa sample at room temperature of 22°C; specifically, a water-cooled mercury lamp is used as the light source, the signal-to-noise ratio of FTIR exceeds 10000:1, and the resolution is 4cm -1 128 scans were performed at a scanning speed of 5kHz to collect spectral data in the band of 0.9-20THz; FTIR has good scanning accuracy, and the jitter rate during the measurement process is less than 3%; before spectrum measurement, the spectrum software OPUS is used to scan the suppressed COC background, eliminate the background and record the scanning results; during the spectrum acquisition process, 30 spectra are collected for each sample.
4. The evaluation model of moxa quality and efficacy based on terahertz technology as claimed in claim 3, characterized in that: The spectral data obtained also include the use of Origin2018 was used to perform baseline correction, smoothing, and normalization of the spectra, and modeling analysis was performed; Gaussian-09 was used to calculate molecular vibrations; IBM SPSS Statistics 26.0 was used for medical indicator data analysis.
5. The evaluation model of moxa quality and efficacy based on terahertz technology as claimed in claim 4, characterized in that: In step S2, a rat model of rheumatoid arthritis is established by injection of complete Freund's adjuvant, so that the left hind paw of the rat develops redness, nodules and limited movement to varying degrees.
6. The evaluation model of moxa quality and efficacy based on terahertz technology as claimed in claim 1, characterized in that: Specifically, step S3 uses a high-precision thermal imager to measure the surface temperature of the acupoints and maintain it between 40°C and 45°C to reduce the result differences caused by temperature variables and prevent local excessive temperature from causing burns to the rats. The model group and the moxibustion group were subjected to the same grasping and fixation treatments, but no moxibustion treatment was performed.
7. The evaluation model of moxa quality and efficacy based on terahertz technology as claimed in claim 1, characterized in that: In step S3, before intervention and after the 2nd, 4th and 7th intervention, i.e., on the 3rd, 5th, 9th and 15th days, the joint swelling degree (JSD), mechanical pain threshold (PWT) and paw withdrawal latency (PWL) were recorded in turn; after the treatment, the concentrations of interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin 6 (IL-6) in the synovial tissue of the left hind paw joint of each group of rats were detected; the detection process was repeated three times and the average value was taken.
8. The evaluation model of moxa quality and efficacy based on terahertz technology as claimed in claim 1, characterized in that: Step S5 specifically includes the following steps: S51. Since the range of RMSE values has no upper and lower limits and is related to the actual data units, it is necessary to standardize the units when comparing different data sets and determine its reasonable range of values based on specific applications. S52. Among the three PLS models for behavioral assessment, the modeling set R for JSD 2 The RMSE of the modeling set is 0.929, the RMSE of the prediction set is 0.169, and the R 2 is 0.907, the prediction set RMSE is 0.139, and the RPD is 3.279; For the PWT modeling set R 2 is 0.904, the RMSE of the modeling set is 0.0000578, and the R 2 is 0.933, the prediction set RMSE is 0.0000535, and the RPD is 3.863; for the modeling set R 2 is 0.957, the RMSE of the modeling set is 1.168, and the R 2 The predicted value is 0.932, the RMSE of the prediction set is 1.438, and the RPD is 3.835.
Citation Information
Cited By
Quality evaluation method and system for three-dimensional cooperation of moxa shaping energy and moxa adulteration identification method
CN122651692A
